These terms and conditions govern your use of the services that we provide and forms a legally binding agreement between you and Otsuka Australia Pharmaceutical Pty Ltd ACN 601 768 754 (Otsuka).

By visiting the IMADJIN® Program website, you acknowledge and agree:

  • that you are a registered healthcare professional in New Zealand and the information you have provided is true and accurate
  • the IMADJIN® Program website is for healthcare professional use only and the password must never be shared with patients
  • to comply with all legislation that applies to you as a healthcare professional including but not limited to all privacy law
  • To the fullest extent permitted by law, in no event shall Otsuka be liable to you for any loss, injury or damages (including but not limited to any special, indirect, consequential or punitive damages, lost profits, lost revenues or other incidental damages, even if advised of the possibility of such damages) arising out of the use, inability to use, or the results of the use of the website. You acknowledge and agree that your sole remedy (and Otsuka’s exclusive liability) for any dispute regarding or in connection with the website and/or your use thereof is to stop using the website.



JINARC® Prescription Medicine (tolvaptan tablets). JINARC® is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease. Before prescribing JINARC, please refer to the full Data Sheet for information on dosage, contraindications, precautions, interactions and adverse effects. Because of the risk of liver injury, prescriber education and certification on the risk of liver injury and the importance of regular liver function monitoring is mandatory. These are available through the IMADJIN® Program, which is run and maintained by, or for, Otsuka Australia Pharmaceutical Pty. Ltd. Further information on the IMADJIN® Program is available at www.jinarc.co.nz or by telephone at 0800 602 200. Date of Preparation of TAPS Mandatories: 23 Sep 2022

JINARC is a funded medicine subject to the restrictions of the Special Authority prescribing and patient eligibility criteria. Review full Data Sheet before prescribing. Approved Data Sheet is available from Otsuka Australia Pharmaceutical Pty Ltd Ph 0800 602 200 or at https://www.medsafe.govt.nz/Profs/Datasheet/j/jinarctabcomb.pdf.